5.22

4.19% 0.21

Pre-market: 5.23 0.01 +0.19%

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $5.22, with a volume of 312.02K. It is up +4.19% in the last 24 hours and up +19.45% over the past month. Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Previous Close:

$5.01

Open:

$5.08

24h Volume:

312.02K

Relative Volume:

0.85

Market Cap:

$72.02M

Revenue:

Net Income/Loss:

$-56.20M

P/E Ratio:

-0.8392

EPS:

-6.22

Net Cash Flow:

$-39.97M

1W Performance:

+11.78%

1M Performance:

+19.45%

6M Performance:

-53.93%

1Y Performance:

-55.38%

1-Day Range:

$5.00

$5.48

1-Week Range:

$4.63

$5.48

52-Week Range:

$4.21

$20.00

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	5.22	72.02M	0	-56.20M	-39.97M	-6.22
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

Jan 19, 2025

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewswire

Jan 14, 2025

Annovis Bio secures US patent for brain injury treatment By Investing.com - Investing.com Nigeria

Jan 14, 2025

Annovis Bio secures US patent for brain injury treatment - Investing.com India

Jan 14, 2025

Annovis Bio Secures Key U.S. Patent for Brain Injury Treatment Breakthrough Buntanetap - StockTitan

Jan 14, 2025

Jan 11, 2025

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo

Jan 11, 2025

Geode Capital Management LLC Has $799,000 Position in Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Jan 11, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of “Buy” by Analysts - Defense World

Jan 11, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives $31.40 Average Price Target from Analysts - MarketBeat

Jan 11, 2025

Jan 10, 2025

Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol - MSN

Jan 10, 2025

Jan 08, 2025

FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study - MSN

Jan 08, 2025

Jan 07, 2025

FDA approves Annovis Bio's updated Alzheimer's trial protocol By Investing.com - Investing.com Canada

Jan 07, 2025

FDA approves Annovis Bio's revised Phase 3 AD study protocol By Investing.com - Investing.com Canada

Jan 07, 2025

Annovis Bio stock slips after Alzheimer’s update (ANVS:NYSE) - Seeking Alpha

Jan 07, 2025

Annovis Bio, Inc. Announces FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer?s Disease Study, Streamlining Development Pathway - Marketscreener.com

Jan 07, 2025

FDA approves Annovis Bio's updated Alzheimer's trial protocol - Investing.com

Jan 07, 2025

FDA approves Annovis Bio's revised Phase 3 AD study protocol - Investing.com

Jan 07, 2025

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway - GlobeNewswire

Jan 07, 2025

Annovis Bio Streamlines Phase 3 Alzheimer's Trial After FDA Approval, Accelerates Path to Market - StockTitan

Jan 07, 2025

Jan 04, 2025

State Street Corp Increases Stock Holdings in Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Jan 04, 2025

Jan 01, 2025

How To Trade (ANVS) - Stock Traders Daily

Jan 01, 2025

Dec 31, 2024